Immix Biopharma
IMMX
23 hedge funds and large institutions have $6.32M invested in Immix Biopharma in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 7 closing their positions.
1,150% more call options, than puts
Call options by funds: $25K | Put options by funds: $2K
3% more capital invested
Capital invested by funds: $6.1M → $6.32M (+$213K)
4.48% less ownership
Funds ownership: 14.92% → 10.44% (-4.5%)
8% less funds holding
Funds holding: 25 → 23 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$52.5K |
| 2 |
Jane Street
New York
|
+$32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
| 4 |
Morgan Stanley
New York
|
+$12.3K |
| 5 |
BlackRock
New York
|
+$133 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.67M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$150K |
| 3 |
I
INVST
Indianapolis,
Indiana
|
-$40.2K |
| 4 |
TW
TritonPoint Wealth
Chevy Chase,
Maryland
|
-$38.3K |
| 5 |
Millennium Management
New York
|
-$32.1K |
IMMX Hedge Fund Activity: Q4 2024 in Review
23 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2024, worth a combined $6.32M — up 3.5% from $6.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMMX and 5 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $52.5K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.67M sold.
- 23 institutional investors held Immix Biopharma (IMMX) as of Q4 2024, down from 25 in Q3 2024.
- Funds reported $6.32M of Immix Biopharma stock for Q4 2024, up 3.5% quarter-over-quarter.
- 5 funds opened new Immix Biopharma positions in Q4 2024 and 7 closed out, a net change of -2 holders.
- The largest Immix Biopharma buyer in Q4 2024 was FNY Investment Advisers, an estimated $52.5K added.
- The largest Immix Biopharma seller in Q4 2024 was AIGH Capital Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2024.